Counterpoint: Prostate Cancer Life Expectancy Can Not Be Accurately Predicted From Currently Available Tools

Authors: Susan A. McCloskey MD 1 and Michael R. Kuettel MD, PhD, MBA 1
View More View Less
  • 1 From the Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York.

A large and growing percentage of prostate cancers are diagnosed among men of advanced age. Current guidelines stratify treatment recommendations based on life expectancy; therefore, accurate determination of life expectancy is essential. Evidence shows that patient-related factors, including age, comorbidities, and functional status, are critical determinants of life expectancy. Equally strong evidence supports tumor-related factors, including Gleason score, tumor stage, and prostate-specific antigen, and efficacy of treatment. Currently, no available tools comprehensively consider all pertinent factors in determining life expectancy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Michael R. Kuettel, MD, Department of Radiation Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263. E-mail: michael.kuettel@roswellpark.org
  • 1.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin 2007;57:4366.

  • 2.

    Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:12731283.

  • 3.

    Mohler J, Babaian RJ, Bahnson RR. NCCN prostate cancer clinical practice guidelines in oncology, version 2, 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed January 2, 2007.

    • Search Google Scholar
    • Export Citation
  • 4.

    Fowler FJ, McNaughton Collins M, Albertsen PC. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:32173222.

    • Search Google Scholar
    • Export Citation
  • 5.

    Koch MO, Miller DA, Butler R. Are we selecting the right patients for treatment of localized prostate cancer? Urology 1998;5:197202.

  • 6.

    Howard DH. Life expectancy and the value of early detection. J Health Econ 2005;24:891906.

  • 7.

    Yan Y, Carvalhal GF, Catalona WJ. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000;88:11221130.

    • Search Google Scholar
    • Export Citation
  • 8.

    Donovan JL, Frankel SJ, Faulkner A. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ 1999;318:299300.

    • Search Google Scholar
    • Export Citation
  • 9.

    Mettlin CJ, Murphy GP, Cunningham MP. The national cancer database report on race, age, and region variations in prostate cancer treatment. Cancer 1997;80:12611266.

    • Search Google Scholar
    • Export Citation
  • 10.

    Schwartz KL, Alibhai SM, Tomlinson G. Continued undertreatment of older men with localized prostate cancer. Urology 2003;62:6065.

  • 11.

    Post PN, Kil PJ, Hendrikx AJ. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 1999;84:652656.

  • 12.

    Alibhai SM, Krahn M, Cohen MM. Is there age bias in the treatment of localized prostate carcinoma? Cancer 2004;100:7281.

  • 13.

    Wetle T. Age as a risk factor for inadequate treatment. JAMA 1987;258:516.

  • 14.

    Vigano A, Dorgan M, Bruera E. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999;86:170176.

    • Search Google Scholar
    • Export Citation
  • 15.

    Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469472.

    • Search Google Scholar
    • Export Citation
  • 16.

    Llobera J, Esteva M, Rifa J. Terminal cancer: duration and prediction of survival time. Eur J Cancer 2000;36:20362043.

  • 17.

    Chow E, Davis L, Panzarella T. Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 2005;61:870873.

    • Search Google Scholar
    • Export Citation
  • 18.

    Wilson JR, Clarke MG, Ewings P. The assessment of patient life-expectancy: how accurate are oncologists and urologists? BJU Int 2005;95:794798.

    • Search Google Scholar
    • Export Citation
  • 19.

    Stockler MR, Tattersall MH, Boyer MJ. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2006;94:208212.

    • Search Google Scholar
    • Export Citation
  • 20.

    Krahn MD, Bremner KE, Asaria J. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 2002;60:258263.

    • Search Google Scholar
    • Export Citation
  • 21.

    Albertsen PC, Fryback DG, Storer BE. The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127132.

    • Search Google Scholar
    • Export Citation
  • 22.

    Newschaffer CJ, Otani K, McDonald MK. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000;92:613621.

    • Search Google Scholar
    • Export Citation
  • 23.

    Fried LP, Kronmal RA, Newman AB. Risk factors for 5-year mortality in older adults: the Cardiovasclar Health Study. JAMA 1998;279:585592.

  • 24.

    Inouye SK, Peduzzi PN, Robison JT. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:11871193.

    • Search Google Scholar
    • Export Citation
  • 25.

    Albertsen PC, Hanley JA, Gleason DF. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975980.

    • Search Google Scholar
    • Export Citation
  • 26.

    Sweat SD, Bergstralh EJ, Slezak J. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002;168:525529.

    • Search Google Scholar
    • Export Citation
  • 27.

    Dahm P, Silverstein AD, Weizer AZ. When to diagnose and how to treat prostate cancer in the ``not too fit'' elderly. Crit Rev Oncol Hematol 2003;48:123131.

    • Search Google Scholar
    • Export Citation
  • 28.

    Albertsen PC, Fryback DG, Storer BE. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626631.

    • Search Google Scholar
    • Export Citation
  • 29.

    Chodak GW, Thisted RA, Gerber GS. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242248.

  • 30.

    Partin AW, Kattan MW, Subong EN. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:14451451.

    • Search Google Scholar
    • Export Citation
  • 31.

    Kattan MW, Zelefsky MJ, Kupelian PA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:33523359.

    • Search Google Scholar
    • Export Citation
  • 32.

    Alibhai SM, Naglie G, Nam R. Do older men benefit from curative therapy of localized prostate cancer. J Clin Oncol 2003;21:33183327.

  • 33.

    National Center for Health Statistics. Life Tables of the United States 2002. Available at http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed January 3, 2007.

    • Search Google Scholar
    • Export Citation
  • 34.

    Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001;285:27502756.

  • 35.

    Saltzstein SL, Behling CA. 5- and 10-year survival in cancer patients aged 90 and older: a study of 37,318 patients from SEER. J Surg Oncol 2002;81:113116.

    • Search Google Scholar
    • Export Citation
  • 36.

    Balducci L, Baskin R, Cohen HJ. NCCN senior adult oncology clinical practice guidelines in oncology, version 2, 2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf. Accessed January 2, 2007.

    • Search Google Scholar
    • Export Citation
  • 37.

    Hosking MP, Warner WA, Lobdell CM. Outcomes of surgery on patients 90 years of age or older. JAMA 1989;261:19091915.

  • 38.

    De Groot V, Beckerman H, Lankhorsty GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003;56:221229.

    • Search Google Scholar
    • Export Citation
  • 39.

    Bernabei R, Venturiero V, Tarsitani P. The comprehensive geriatric assessment. Crit Rev Oncol Hematol 2000;33:4556.

  • 40.

    Reuben DB, Rubenstein LV, Hirsch SH. Value of functional status as predictor of mortality. Am J Med 1992;93:663669.

  • 41.

    Inouye SK, Peduzzi PN, Robison JT. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:11871193.

    • Search Google Scholar
    • Export Citation
  • 42.

    Barberger-Gateau P, Fabrigoule C, Helmer C. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 1999;47:456462.

    • Search Google Scholar
    • Export Citation
  • 43.

    Fried L, Tangen C, Walston J. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146156.

  • 44.

    Lachs MS, Feinstein AR, Cooney LM Jr. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990;112:699706.

    • Search Google Scholar
    • Export Citation
  • 45.

    Fleischman SB. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 2004;32:119123.

  • 46.

    Saliba D, Elliott M, Rubnstein LZ. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:16911199.

    • Search Google Scholar
    • Export Citation
  • 47.

    Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003;114:180187.

    • Search Google Scholar
    • Export Citation
  • 48.

    Albertsen PC, Fryback DG, Storer BE. The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127132.

    • Search Google Scholar
    • Export Citation
  • 49.

    Tewari A, Johnson CC, Divine G. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004;171:15131519.

    • Search Google Scholar
    • Export Citation
  • 50.

    Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006;175:99103.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 76 31 0
PDF Downloads 30 18 1
EPUB Downloads 0 0 0